Modified-Release Trazodone for Acute Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Modified-release (MR) trazodone formulations (prolonged-release [PR] and once-a-day [OAD]) are used to treat acute major depressive disorder (MDD), but there has been no quantitative synthesis of the available double-blind randomized evidence. We assessed the efficacy and tolerability of MR trazodone in adults with acute MDD. METHODS: We searched PubMed/MEDLINE, Europe PMC, and ClinicalTrials.gov up to 24 February 2026 and Scopus up to 6 March 2026. We also screened the reference lists of the identified publications for randomized controlled trials (RCTs) of trazodone PR or OAD in adults with acute MDD. Random-effects meta-analyses were performed when at least 2 trials were available. FINDINGS: Five primary RCTs (N=1329 randomized) met the inclusion criteria: 2 were placebo-controlled and 3 were active-controlled. Compared with placebo, MR trazodone improved HAM-D-17 scores (mean difference in symptom improvement: 2.49; 95% CI: 1.48-3.51) and increased the response rate (risk ratio [RR]: 1.44; 95% CI: 1.19-1.75). Remission rates were higher but imprecise (RR: 1.32; 95% CI: 0.93-1.88). Discontinuation due to adverse events occurred more frequently than with placebo (RR: 3.57; 95% CI: 1.79-7.10). In head-to-head trials, the estimates versus SSRIs were imprecise and did not demonstrate equivalence. A single venlafaxine XR trial favored venlafaxine. CONCLUSIONS: On the basis of 2 placebo-controlled trials, MR trazodone was found to be more effective than a placebo for reducing acute adult MDD symptoms in the short term. Sparse active-comparator evidence does not demonstrate superiority or equivalence compared with standard antidepressants. Real-world data may provide complementary information when insomnia or anxious distress is prominent.
Authors
- Fabiola Raffone (ORCID: https://orcid.org/0000-0002-1818-4237)
- Vassilis Martiadis (ORCID: https://orcid.org/0000-0002-3344-1000)
- Enrico Pessina (ORCID: https://orcid.org/0000-0003-0485-6319)
- Azzurra Martini (ORCID: https://orcid.org/0009-0003-4184-236X)
- Antonella Cervino (ORCID: https://orcid.org/0009-0006-5478-5888)
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- Regione Campania (IT)
- ASL Roma (IT)
- Azienda Sanitaria Locale Salerno (IT)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1097/jcp.0000000000002299
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00